LPCAT3 and non-small cell lung carcinoma: Similar to patients with NSCLC, we found that C3F was significantly elevated in serum from patients with SpA (median = 3.73 nM, range = 2.54–13.47 nM) compared to serum from healthy controls (median = 2.54 nM, range = 2.54–6.04 nM) (p = 0.0015) (Figure 3a).